Myovant's Next Act: Commercial Execution And Business Development
The company is ramping up the launches of Orgovyx for prostate cancer and Myfembree for uterine fibroids, including indication and geographic expansions, and evaluating business development opportunities.
You may also be interested in...
Sumitovant offered $22.75 per share in cash, valuing Myovant at $2.4bn total, to acquire what it does not hold as a result of its 2019 agreement to buy majority shares of five Roivant companies.
Myovant CEO David Marek talked to Scrip about why the companies believe patients and physicians will choose Myfembree over AbbVie's Oriahnn.
Facing looming expiries for its top product, Japan’s Sumitomo Dainippon is planning to acquire multiple "vant" companies and their portfolios of clinical stage assets from Roivant, in a move to address mid-term challenges to revenues and following recent late-stage development failures.